Biosimilar development

What does it take to make life-changing treatments?

Biosimilar drug development requires a deep understanding of the reference product.1 This includes analysis and characterization of the reference product to identify its key characteristics.2

Once the reference product has been characterized, live cells are used to develop biosimilar candidates using the following steps:

  • Genetic instructions are inserted into a clone (cell) to produce a specific candidate biologic3
  • After different versions of the biologic are made, each one by a different cell, screening is conducted to identify the cell line that produces the protein that is most similar to the reference product3
  • A process to manufacture the biosimilar is developed, in a way that maximizes the similarity between the biosimilar and the reference product3,4

Compared to reference products, which usually take around 8 to 10 years to reach the market, the time to market for a biosimilar is around 7 to 8 years.5

Development of Fresenius Kabi biosimilars

Equipped with global expertise in biologic development and manufacturing, Fresenius Kabi applies the same high quality standards to developing and producing biosimilars that are required for the development of reference products.

We bring years of pharmaceutical experience and technical knowledge to ensure the production of a consistent, high-quality product.

Fresenius Kabi biosimilars meet the high regulatory standards required by the FDA, based on totality of evidence across analytical, pharmacokinetic/pharmacodynamic (PK/PD), clinical safety and immunogenicity assessments against the reference product.6

Discover more about how biosimilars are manufactured here

Info

Looking for more information?

If you would like to know more about Fresenius Kabi and our unique approach to biosimilars, please get in touch.

Contact Us
Fresenius Kabi

Fresenius Kabi AG © June 2021 1702-BIOS-08-05/21